期刊文献+

超高效液相串联质谱法测定大鼠血浆中(S)-MP 3950的浓度及其药代动力学研究 被引量:1

Determination of( S )-MP 3950 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study
原文传递
导出
摘要 目的建立超高效液相串联质谱(UPLC-MS/MS)法测定新型胃动力候选药(S)-MP 3950在大鼠血浆中的浓度并应用于药代动力学研究。方法血浆样品用乙酸乙酯提取,色谱柱为ACQUITY UPLC~BEH C18柱(2.1 mm×50 mm,1.7μm);流动相为甲醇-5 mmol·L^(-1)醋酸铵(含体积分数为0.1%的甲酸)(55∶45),流速为0.2 mL·min^(-1),柱温30℃;质谱检测用电喷雾离子(ESI)源,正离子模式下采用多反应监测(MRM)模式,分析时间为3.0 min。用DAS 2.0软件以非房室模型计算药代动力学参数。结果 (S)-MP 3950在大鼠血浆中的线性范围为10~5000μg·L^(-1)。定量下限为10μg·L^(-1)。日内、日间精密度(RSD)均不大于7.9%,准确度(RE)为0.1%~8.5%。结论此方法快速、灵敏,准确,成功应用于大鼠血浆中(S)-MP 3950浓度的测定及其药代动力学研究。 Objective To develop an ultra performance liquid chromatography- tandem mass spectrometry( UPLC- MS / MS) method for the study of pharmacokinetics of( S)- MP 3950,a novel gastroprokinetic agent candidate in rats. Methods The plasma samples were extracted by liquid- liquid extraction( LLE) with ethyl acetate. An ACQUITY UPLC~BEH C(18)column( 2. 1 mm × 50 mm,1. 7 μm) was used with a mobile phase consisting methanol and 5 mmol · L^-1ammonium acetate with 0. 1% formic acid( v ∶ v = 45 ∶ 55). The analysis was performed in multiple reaction monitoring( MRM) mode via positive electrospray ionization source on a triple quadrupole tandem mass spectrometer. The whole analysis time was 3. 0 min. The pharmacokinetic parameters were calculated by DAS 2. 0 program. Results The method had a lower limit of quantification( LLOQ) of 10 μg·L^-1,linear up to 5000 μg·L^-1.The intra- and inter- day precision( relative standard deviation,RSD)were all less than 7. 9%. The accuracy( relative error,RE) was from0. 1% to 8. 5%. Conclusion The method was proved to be rapid,sensitive and accurate for pharmacokinetic study of( S)- MP 3950 in rats.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第13期1227-1230,共4页 The Chinese Journal of Clinical Pharmacology
关键词 (S)-MP 3950 超高效液相串联质谱法 药代动力学 (S)-MP 3950 ultra performance liquid chromatographytandem mass spectrometry pharmacokinetics
  • 相关文献

参考文献6

  • 1CURRAN M P, ROBINSON D M. Mosapride in gastrointestinal dis- orders[J]. Drugs, 2008, 68(7):981 -991.
  • 2YOSHIKAWA T, YOSHIDA N, MINE Y, et al. Affinity of mosa- pride citrate, a new gastroprokinetic agent, for 5 - HT4 receptors in guinea pig ileum [J]. Jpn J Phaol, 1998,77(1 ) :53 -59.
  • 3赵龙山,王绍杰,何仲贵,等.莫沙必利的活性代谢物及其制备方法和用途:CN104961646A[P].2015-10-07.
  • 4ZHAO L S, SUN X H, XIONG Z L, et al. Simultaneous determina- tion of mosapride and its active des - p - fluorobenzyl and 4' - N - oxide metabolites in rat plasma using UPLC - MS/MS : An application for a pharmacokinetic study [ J]. Talanta, 2015, 137 (2) : 130 - 135.
  • 5US Food and Drug Administration. Guidance for industry, bioanalyti- cal method validation [ EB/OL]. 2001 - 05 - 01 [ 2016 - 03 - 06]. http://www, fda. gov/downloads/Drugs/GuidanceComplianceRegu- latorylnformation/Guidances/UCM070107, pdf.
  • 6NOVAKOVA L, VLCKOVA H. A review of current trends and ad- vances in modern bio - analytical methods : chromatography and sam- ple preparation [J]. Anal Chim Acta, 2009, 656( 1 -2) :8 -35.

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部